UBS AM’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-66,433
Closed -$8.82M – 4249
2026
Q2
$8.82M Buy
66,433
+10,081
+18% +$908K ﹤0.01% 1314
2026
Q1
$4.74M Buy
56,352
+6,547
+13% +$475K ﹤0.01% 1577
2025
Q4
$3.76M Buy
49,805
+18,642
+60% +$1.17M ﹤0.01% 1600
2025
Q3
$1.24M Sell
31,163
-23,899
-43% -$913K ﹤0.01% 1938
2025
Q2
$2.39M Buy
55,062
+19,336
+54% +$736K ﹤0.01% 2070
2025
Q1
$1.33M Buy
35,726
+3,465
+11% +$134K ﹤0.01% 2185
2024
Q4
$1.46M Buy
32,261
+20
+0.1% +$1.02K ﹤0.01% 2190
2024
Q3
$1.89M Sell
32,241
-2,162
-6% -$104K ﹤0.01% 2063
2024
Q2
$1.35M Buy
+34,403
New +$1.67M ﹤0.01% 2209

Other funds holding APGE

UBS AM's APGE Position: Q3 2026 in Review

UBS AM sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 66,433 shares — an estimated $8.82M sold.

UBS AM first reported a position in APGE in Q2 2024 and held it in 9 quarters. The position peaked at $8.82M in Q2 2026. 3 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • UBS AM reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • UBS AM sold 66,433 Apogee Therapeutics shares in Q3 2026, an estimated $8.82M.
  • UBS AM first reported a position in Apogee Therapeutics in Q2 2024 and held it in 9 quarters.
  • UBS AM's Apogee Therapeutics position peaked at $8.82M in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.